Multiple System Atrophy
Conditions
Keywords
dysexecutive syndrome, multiple system atrophy, imaging study
Brief summary
The main objective of the study is to compare the score to the Behavioral Dysexecutive Syndrome Inventory (BDSI) between Parkinsonian Multiple system Atrophy MSA-P patients and cerebellar Multiple System Atrophy (MSA-C) patients matched on disease duration, age (± 7 years) and sex .
Detailed description
Multiple system atrophy (MSA) is a rare neurodegenerative disorder which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. According to the consensus criteria for the diagnosis of MSA, the presence of dementia is considered an exclusion criteria. However, several studies have reported cognitive impairment in patients with MSA, dominated by a dysexecutive syndrome. Some studies have compared the cognitive profile of MSA-P patients and MSA-C but any have studied the behavioral dysexecutive syndrome in this population. In 2010, the GREFFEX has established criteria for dysexecutive syndrome and described two distinct parts: the dysexecutive syndrome and cognitive behavioral dysexecutive syndrome. Our clinical impression is that according to the type of MSA, the dysexecutive syndrome seems to be different : the MSA-P patients seem to have a cognitive dysexecutive syndrome and the MSA-C patients a behavioral dysexecutive syndrome. We want to compare the BDSI score between MSA-P patients and MSA-C patients matched on disease duration, age and sex The specific involvement of the cerebellum in behavioral disorders could explain the behavioral differences experienced by clinicians caring for these patients but never demonstrated. The presence of these disorders could have an impact on the relationship between the patient and the caregiver. In addition, few studies have correlated with cognitive imagery data. Therefore, the exact areas involved in cognitive and behavioral MSApatients remain poorly understood.
Interventions
OTHERClinical evaluation
OTHERneuropsychological battery test
OTHERMRI
OTHERActigraphy
Actigraphy recording will be performed during 7 days after inclusion.
Sponsors
University Hospital, Bordeaux
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients suffering from probable MSA according to clinical consensus criteria (Gilman et al, 2008), * Age \>30 * Written informed consent * Patient covered by the national health system * The presence of an informant * Blood negative dosage of the hormone béta-hCG for the women old enough to procreate
Exclusion criteria
* UMSARS IV score \> 4 points * Pregnant woman (blood positive dosage of the hormone béta-hCG) or breast feeding * Patient under tutelage * Patient unable to give consent * Against indication to perform an MRI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Behavioral Dysexecutive Syndrome Inventory scores | At inclusion (day 0) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To compare the cognitive tests exploring the cognitive dysexecutive syndrome between MSA-P patients and MSA-C patients. | At inclusion (Day 0) | * Trail making Test * Stroop Test * Modfied Card Sorting Test * Brixton Test * Verbal fluency Test * Six Elements Test |
| To research correlations between scores UMSARS and cognitive and behavioral scores for MSA-P patients and MSA-C patients. | At inclusion (Day 0) | Assessment using the Behavioral Dysexecutive Syndrome Inventory |
| To compare the subscores of the BDSI between MSA-P patients and MSA-C patients. | At inclusion (Day 0) | — |
| To research correlations between imaging abnormalities and cognitive test performance in MSA patients. | At inclusion (day 0) | — |
| Actigraphy | During 7 days after inclusion | Sleep analysis : Sleep / wake cycles and sleep fragmentation |
| To compare atrophied brain areas, the anatomic and functional abnormalities of neural networks between MSA-P patients and MSA-C patients. | At inclusion (Day 0) | — |
Countries
France
Outcome results
None listed